Anteris Technologies Global Corp. announced the successful closing of a combined $320 million capital raise, consisting of a $200 million underwritten public offering of 40 million common shares at $5.75 per share and a $120 million private placement of 15,652,173 shares to Medtronic plc. Joint book-running managers for the public offering included Barclays, Wells Fargo Securities and Cantor Fitzgerald, while Wells Fargo Securities served as sole placement agent for the private placement. The gross proceeds, before underwriting discounts, placement agent fees and estimated expenses, totaled approximately $320 million.

The private placement to Medtronic represents a strategic investment designed to strengthen Anteris’s position in the transcatheter heart valve market. Medtronic’s equity commitment follows the public offering and creates a partnership framework for potential future collaborations. Medtronic’s interest underscores confidence in Anteris’s DurAVR® Transcatheter Heart Valve technology and its differentiated biomimetic approach, which uses a single piece of molded ADAPT® tissue with over 10 years of clinical data and more than 55,000 patients treated.

Anteris intends to allocate net proceeds alongside existing cash to three primary objectives: execute patient enrollment and study execution in the global PARADIGM Trial for severe aortic stenosis; expand manufacturing capacity for commercial-scale production of the DurAVR® THV and its ComASUR® Delivery System; and fund ongoing research and development through its v2vmedtech subsidiary. The PARADIGM Trial, which commenced first-patient implants in Denmark in Q4 2025, is a pivotal randomized controlled study targeting up to 1,000 patients to compare safety and efficacy against leading commercially available devices.

Following the capital raise, Anteris’s cash position is bolstered to support its global clinical strategy and regulatory submissions. The company expects to finance working capital and general corporate purposes from the remaining proceeds. With a science-driven management team and operations spanning Minneapolis and Brisbane, Anteris is positioned to advance its biomimetic valve platform toward market approval and potential commercialization in multiple geographies.